- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Non-familial hypercholesterolaemia Familial heterozygous hypercholesterolaemia
- Meeting Date: November 2024
- Public Summary Document (PSD) November 2024 PBAC Meeting - (PDF 459KB)
- Public Summary Document (PSD) November 2024 PBAC Meeting - (Word 92KB)
Inclisiran – November 2024
Inclisiran (restriction level); Injection 284 mg in 1.5 mL single use pre-filled syringe; Leqvio®
Last updated
30 May 2025